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We welcome you to a special issue of Neurotherapeutics that
highlights much of the exciting new thinking behind a
burgeoning and therapeutically relevant topic—epigenetic pro-
teins in psychiatric and neurological disease. It is now well
established that expression of single genes or gene cassettes is
determined by the interplay between transcription factors and
epigenetic modulators. Epigenetics literally means “above the
genome” and is defined by modifications of DNA, as well as
chromatin that ultimately affect gene expression. Accordingly,
epigenetic markers can be considered similar to punctuation
marks in the English language. They define the beginning and
the end of a gene; they structure the chromosomes; and they
alter how the information is read, either activating or silencing
transcription.
Defining Epigenetics: You Say Tomato I Say Tomahto
The term epigenetics was first coined byWaddington in 1942.
At its conception, epigenetics referred to a field that focused
on how the genotype is related to the phenotype [1]. In 1996,
Arthur Riggs restricted the definition to the study of mitoti-
cally hereditable changes in gene expression that occur with-
out changes in DNA sequence [2]. Thanks to advanced tech-
nologies in genomics and gene profiling, the new millennium
saw the explosion of epigenetics and revealed is relevance to
diverse processes in biology. According to Adrian Bird, epi-
genetics is “the structural adaptation of chromosomal regions
so as to register, signal or perpetuate altered activity states”
[3]. This latter definition will likely offend the purists, who,
justifiably, see epigenetics in a restricted way as heritable
changes in gene expression that cannot be explained by the
codes of genes themselves [4, 5]. However, Bird’s definition
encompasses this traditional view of epigenetics and herita-
bility, and is congruent with the notion that biological pro-
cesses are modular, and there is selective pressure for proteins
to adopt new functions that do not substitute or exclude the
functions on which they were defined. Indeed, advances in
technology have shown us that epigenetic changes can occur
with great regularity over minutes in yeast reproducibly at
distinct phases of the cell cycle. Accordingly, we now recog-
nize that the kinetics of changes in epigenetic proteins, and, by
extension, gene expression, can happen rapidly or slowly and
are heritable or nonheritable, but all engage proteins or RNA
that sit just above the genome, and thus qualify as part of a
newer, biologically more multicultural and progressive field
of epigenetics. The challenge for biologists and clinical
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scientists will be to understand the regulators that differentiate
this kinetics, so that therapeutic manipulations of these pro-
cesses can be optimized and do not cause unexpected and
durable changes through generations.
Epigenetics and Therapeutics in the Nervous System:
Beyond Faddism
This issue should provide the reader with a comprehensive
review of the most relevant epigenetic marks and modulators;
it will present examples of dysregulated epigenetic mechanisms
occurring in neuronal injury and neurodegenerative diseases;
finally, this issue will describe the state of the art for small
molecules to be able to target and correct these epigenetic
mechanisms. The outstanding articles presented byworld leaders
in their respective fields offer new hope for the treatment ofmany
acute and chronic central nervous system conditions (Fig. 1).
The issue is divided into 2 major sections, with the first
section devoted to distinct families of epigenetic modifications,
with some discussion of available small molecule modulators
of these distinct types of modifications. The first part of the first
section describes classical and emerging views of chemical
modifications of DNA that affect gene expression—a process
that is far more dynamic than once considered. In the review by
Weng et al. (p. XX) [6], a comprehensive description of DNA
methylation and demethylation, the implication of alteredmeth-
ylation state in neurodegenerative diseases, and the description
of pharmacological and molecular approaches to correct aber-
rant methylation state of the DNA are described.
Chromatin is composed of DNA wrapped around histone
proteins. The smallest functional unit of chromatin is called a
nucleosome, where the DNA is wrapped one and three quarter
times around a histone octamer. Histone proteins are rich in
positively-charged amino acids, creating an electrostatic inter-
action with the negatively-charged DNA. Post-translational
modifications of histones can alter the structure of the chro-
matin, creating a compact or open structure. For example, the
balance between chromatin acetylation and deacetylation cor-
relates with active and repressed transcriptional states. One
way to bias histone acetylation in favor of transcription is via
histone acetyltransferase (HAT) activity. In the review by
Schneider et al. (p. XX) [7], a detailed description of the most
promising HAT activators is reported.
The complementary strategy to HAT activation is histone
deacetylase (HDAC) inhibition—a strategy that has been
utilized for therapeutic success in the brain, spinal cord, and
peripheral nervous system. A complete description of the
state-of-the-art for selective HDAC inhibitors is reported in
the review by Wagner et al. (p. XX) [8]. The description of
HDAC inhibitors is focused on small molecules that target
class I, II, and IV HDACs, where all the constituents share a
conserved structure and present a zinc catalytic site binding.
Conversely, class III HDACs are characterized by nicotin-
amide adenine dinucleotide+-binding enzymes called Sirtuins.
In the review by Langley and Sauve (p. XX) [9], the involve-
ment of sirtuins in disease mechanisms is carefully described.
The mechanisms that determine which part of the genome
are silenced or activated are evolving, and recent discoveries
have highlighted the importance of noncoding RNAs in mod-
ulating or recruiting some of the factors responsible for laying
down the marks or removing them. There are many classes of
noncoding RNAs and 2 articles focus on 2 of the most studied
classes: the microRNAs (Varela et al., p. XX [10]) and long
noncoding RNAs (Quereshi and Mehler, p. XX [11]).
Interestingly, not only have epigenetic regulators been
reported to be dysregulated in neurological and psychiatric
conditions, there is also evidence that the use of small mole-
cules targeting different elements of the epigenome can be a
promising therapeutic approach. In the second section of this
issue, we have tried to create a reference that summarizes the
most interesting results reported in aging, as well as neurolog-
ical and psychiatric conditions that span from monogenic
diseases to multifactorial genetic and sporadic syndromes,
and acute injuries. For all of these conditions, the environment
is recognized to play an important role.
Zhao et al. (p. XX) [12] elaborately describe the active role of
epigenetic regulation in neurobiology and emphasize the epige-
netic changes that occur during normal aging. In Huntington’s
disease, caused by a trinucleotide expansion in the coding gene
of huntingtin, transcriptional dysregulation has been thoroughly
characterized. Accordingly, malfunction in all the epigenetic
players like histone acetylation, methylation, DNA methylation,
and noncoding RNAwas reported, suggesting that a combinato-
rial therapy targeting several of these mechanisms could be a
promising strategy (Lee et al., p. XX [13]). Conversely, in spinal
muscular atrophy, another disease characterized by nucleotide
repeats in a coding region of the gene, only HDAC inhibitors
provided positive results in both in vitro and in vivo models of
the disease, leading to the design of several clinical trials in
humans, as described by Lunke et al. (p. XX) [14]. HDAC
inhibitors have also been shown to rescue defects observed in
Niemann-pick disease type C, which may have relevance for
other disorders involving cognitive abnormalities (Helquist et al.
p. XX [15]).
Multifactorial diseases, such as Parkinson’s disease (Kaidery
et al., p. XX [16]) and Alzheimer’s disease (Sai Veerappan, p.
XX [17]), are an interesting example of how the environment
can modulate the genome and contribute to the outcome of
neurodegenerative conditions. In amyotrophic lateral sclerosis,
Martin and Wong (p. XX) [18] instead discuss the importance
of DNA methylation and present potential therapeutic role of
pharmacological inhibitors by targeting Dnmt3a activity. Final-
ly, several psychiatric disorders are characterized by transcrip-
tional impairments (Mahgoub and Monteggia, p. XX [19]).
Despite the lack of evidence for therapeutics targeting the
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Fig. 1 A symbolic view of the role that epigenetic proteins and RNA can play in unlocking new therapeutics for challenging neurological and
pyschiatric conditions
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epigenome, Rangasamy et al. (p. XX) [20] extensively summa-
rize the epigenetic alterations reported in the autism spectrum
disorders (Angelman syndrome, Prader–Willi syndrome, frag-
ile X syndrome, and Kabuki syndrome).
York et al. (p. XX) [21] describe the complexity of spinal
cord injury, where several cellular populations (injured neu-
rons, astrocytes, and oligodendrocytes) are affected and man-
ifest epigenetic alterations. The activity of small molecule
HDAC inhibitors proved to be beneficial in each of these
populations by engaging the repair processes. Similarly,
Linder et al. (p. XX) [22] provide a comprehensive overview
of the injury-induced mechanisms that can halt neuronal re-
generation, and highlight the potential of epigenetic modula-
tors in correcting the activity of central genes like CREB1 . To
complete the overview on the role of glial cells in acute and
chronic diseases, and their response to epigenetic therapeutics,
Garden (p. XX) [23] reviews the most exciting outcomes in
neuroinflammation. In another acute neuronal injuries, such as
stroke, HDACs seem to be the major class of epigenetic
regulators involved both in preconditioning (Thompson, p.
XX [24]) and neuronal repair (Baltan et al., p. XX [25]).
Selective isoforms responsible for the damaging effects are
currently under investigation (Baltan et al., p. XX [25] and
Edward Holson et al., p. XX [8]). The role of epigenetic
proteins in neural plasticity and stroke rehabilitation is also
reviewed, with a particular focus on polycomb proteins, aden-
osine triphosphate-dependent chromatin modifiers, and the
role of HDACs in hippocampal-based plasticity mechanisms
(Elder et al., p. XX [26]).
Finally, chromatinmodifications appear to play a role in DNA
repair after damage. As elegantly summarized by Brochier and
Langley (p. XX) [27], DNA damage participates in the patho-
genic mechanisms involved in aging, stroke, spinal cord injury,
Alzheimer’s disease, Huntingdon’s disease, Parkinson’s disease,
and amyotrophic lateral sclerosis, and the broad salutary effects
of HDAC inhibition in models of these conditions may be
mediated via effects on DNA damage.
Emerging Areas
The role of epigenetic modulators in physiology and disease in
the nervous system is moving so rapidly that even the compre-
hensive set of articles presented here cannot entirely capture all
of the most exciting and current advances in the field. Notably,
articles focused on histone methylation and other novel post-
translational modifications of histones (e.g., succinylation, gly-
cosylation, citrullination, etc.) are not included, and the reader
is referred to an outstanding review in this area [28]. Moreover,
burgeoning interest in cell metabolism in the context of cancer
and neurodegenerative disease has stimulated much interest in
how specific metabolic changes in glucose metabolism and its
downstream metabolites are converted into changes in gene
expression via epigenetic proteins. Many of these epigenetic
proteins utilize metabolic substrates as cofactors and thus
directly connect environmental metabolic changes into
changes in gene expression [29]. Finally, it is now recognized
that sequence variants in histone proteins provide another
mechanism to generate diversity in chromatin structure and
function. These studies have been led, to a good degree,
by David Allis, the father of the concept of the histone code
[30, 31].
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